Skip to Content
Merck
CN
All Photos(1)

Key Documents

View All Documentation

Safety Information

B8063

Sigma-Aldrich

BML-210

≥98% (HPLC), powder

Synonym(s):

N1-(2-aminophenyl)-N8-phenyl-octanediamide

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C20H25N3O2
CAS Number:
537034-17-6
Molecular Weight:
339.43
MDL number:
MFCD08062139
UNSPSC Code:
12352200
PubChem Substance ID:
329773304
NACRES:
NA.77

Quality Level

100

Assay

≥98% (HPLC)

form

powder

color

white to very faintly yellow

solubility

DMSO: >20 mg/mL

storage temp.

2-8°C

SMILES string

Nc1ccccc1NC(=O)CCCCCCC(=O)Nc2ccccc2

InChI

1S/C20H25N3O2/c21-17-12-8-9-13-18(17)23-20(25)15-7-2-1-6-14-19(24)22-16-10-4-3-5-11-16/h3-5,8-13H,1-2,6-7,14-15,21H2,(H,22,24)(H,23,25)

InChI key

RFLHBLWLFUFFDZ-UHFFFAOYSA-N

Biochem/physiol Actions

BML-210 is a histone deacetylase inhibitor. Treatment of A549 cells with BML-210 results in a dose-dependent increase in acetylated histone levels (EC50 = 36 μM). In HeLa extracts, the IC50 for inhibition of HDAC activity is 80 μM.
BML-210 is a synthetic benzamide and is a potential tumor inhibitor. It is used as a therapeutic agent to treat promyelocytic leukemia. In human leukemia cell lines (NB4, HL-60, THP-1, and K562), BML-210 modulates histone deacetylase and promotes apoptosis. BML-210 favors frataxin expression in neurodegenerative disease Friedreich′s ataxia (FRDA). It interacts with myocyte enhancer factor-2 (MEF2) via hydrogen-bonding and prevents histone deacetylase 4 (HDAC4) binding.
BML-210 is an HDAC inhibitor.

Features and Benefits

This compound is a featured product for Gene Regulation research. Click here to discover more featured Gene Regulation products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.

Hazard Statements

H413

Precautionary Statements

P273 - P501

Hazard Classifications

Aquatic Chronic 4

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Regulatory Information

新产品

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
0000185793
0000185792
0000185793
0000185792
021M4616V

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Veronika Borutinskaitė et al.
International journal of molecular sciences, 16(8), 18252-18269 (2015-08-20)
Today, cancer is understood as an epigenetic as well as genetic disease. The main epigenetic hallmarks of the cancer cell are DNA methylation and histone modifications. Proteins such as histone deacetylases (HDACs) that cause modifications of histones and other proteins
Natalia Sacilotto et al.
Genes & development, 30(20), 2297-2309 (2016-11-30)
Angiogenesis, the fundamental process by which new blood vessels form from existing ones, depends on precise spatial and temporal gene expression within specific compartments of the endothelium. However, the molecular links between proangiogenic signals and downstream gene expression remain unclear.
The novel histone deacetylase inhibitor BML-210 exerts growth inhibitory, proapoptotic and differentiation stimulating effects on the human leukemia cell lines
Savickiene J, et al.
European Journal of Pharmacology, 549(1-3), 9-18 (2006)
The histone deacetylase inhibitor BML-210 influences gene and protein expression in human promyelocytic leukemia NB4 cells via epigenetic reprogramming
Borutinskaite V and Navakauskiene R
International Journal of Molecular Sciences, 16(8), 18252-18269 (2015)
Inhibition of the function of class IIa HDACs by blocking their interaction with MEF2
Jayathilaka N, et al.
Nucleic Acids Research, 40(12), 5378-5388 (2012)
View All Related Papers

Articles

Discover Bioactive Small Molecules for Gene Regulation

We offer a variety of small molecule research tools, such as transcription factor modulators, inhibitors of chromatin modifying enzymes, and agonists/antagonists for target identification and validation in gene regulation research; a selection of these research tools is shown below.

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service